CMX001: Phase I/II data

A double-blind, U.S. Phase I/II trial in 12 renal transplant and 11 hematopoietic stem cell transplant (HSCT) patients showed that 5 weekly doses of 40 mg oral CMX001 were well tolerated with no signs...